二价HPV疫苗对HPV16/18相关癌前病变的长期效力:哥斯达黎加疫苗试验随访结果
哥斯达黎加疫苗试验将18-25岁女性随机分配接种二价HPV疫苗或对照甲肝疫苗,长期随访至11年。
要点
- 长期随访中未观察到与HPV疫苗相关的严重不良事件。
核心结论
- 二价HPV疫苗在初次接种后十余年对HPV16/18相关癌前病变保持高效力,支持浸润性宫颈癌可预防的结论。
研究设计与样本
- 随机双盲对照试验纳入18-25岁女性7466人,按1:1分配接种二价HPV16/18 AS04佐剂疫苗或对照甲肝疫苗。
- 盲态期4年结束后,疫苗组受邀进入长期随访延长7年,原对照组接种HPV疫苗并替换为新未接种对照组,随访至第11年。
- 疫苗效力分析队列为接种时HPV16/18 DNA阴性女性,主要终点为组织病理学确诊的HPV16/18相关CIN2+。
主要发现
- 长期随访中无与HPV疫苗相关的严重不良事件;最常见的3级或以上严重不良事件为妊娠、产褥期和围产期状况(未接种组2530人中255人[10%],疫苗组2073人中201人[10%])。
- 未接种组4人死亡、疫苗组3人死亡,均未判定与HPV疫苗相关。
临床怎么用
- 为适龄女性接种二价HPV疫苗可提供十余年针对HPV16/18相关癌前病变的高水平保护。
- 长期随访安全性数据支持二价HPV疫苗的持续使用。
局限性
- 长期随访阶段研究者和受试者知晓治疗分配,非盲态设计可能引入偏倚。
- 长期随访中对照组替换为新未接种队列,两组随访时长和基线特征可能存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oncogenic human papillomavirus (HPV) infections cause most cases of cervical cancer. Here, we report long-term follow-up results for the Costa Rica Vaccine Trial (publicly funded and initiated before licensure of the HPV vaccines), with the aim of assessing the efficacy of the bivalent HPV vaccine for preventing HPV 16/18-associated cervical intraepithelial neoplasia grade 2 or worse (CIN2+). METHODS: Women aged 18-25 years were enrolled in a randomised, double-blind, controlled trial in Costa Rica, between June 28, 2004, and Dec 21, 2005, designed to assess the efficacy of a bivalent vaccine for the prevention of infection with HPV 16/18 and associated precancerous lesions at the cervix. Participants were randomly assigned (1:1) to receive an HPV 16/18 AS04-adjuvanted vaccine or control hepatitis A vaccine. Vaccines were administered intramuscularly in three 0·5 mL doses at 0, 1, and 6 months and participants were followed up annually for 4 years. After the blinded phase, women in the HPV vaccine group were invited to enrol in the long-term follow-up study, which extended follow-up for 7 additional years. The control group received HPV vaccine and was replaced with a new unvaccinated control group. Women were followed up every 2 years until year 11. Investigators and patients were aware of treatment allocation for the follow-up phase. At each visit, clinicians collected cervical cells from sexually active women for cytology and HPV testing. Women with abnormal cytology were referred to colposcopy, biopsy, and treatment as needed. Women with negative results at the last screening visit (year 11) exited the long-term follow-up study. The analytical cohort for vaccine efficacy included women who were HPV 16/18 DNA-negative at vaccination. The primary outcome of this analysis was defined as histopathologically confirmed CIN2+ or cervical intraepithelial neoplasia grade 3 or worse associated with HPV 16/18 cervical infection detected at colposcopy referral. We calculated vaccine efficacy by year and cumulatively. This long-term follow-up study is registered with ClinicalTrials.gov, NCT00867464. FINDINGS: 7466 women were enrolled in the Costa Rica Vaccine Trial; 3727 received the HPV vaccine and 3739 received the control vaccine. Between March 30, 2009, and July 5, 2012, 2635 women in the HPV vaccine group and 2836 women in the new unvaccinated control group were enrolled in the long-term follow-up study. 2635 women in the HPV vaccine group and 2677 women in the control group were included in the analysis cohort for years 0-4, and 2073 women from the HPV vaccine group and 2530 women from the new unvaccinated control group were included in the analysis cohort for years 7-11. Median follow-up time for the HPV group was 11·1 years (IQR 9·1-11·7), 4·6 years (4·3-5·3) for the original control group, and 6·2 years (5·5-6·9) for the new unvaccinated control group. At year 11, vaccine efficacy against incident HPV 16/18-associated CIN2+ was 100% (95% CI 89·2-100·0); 34 (1·5%) of 2233 unvaccinated women had a CIN2+ outcome compared with none of 1913 women in the HPV group. Cumulative vaccine efficacy against HPV 16/18-associated CIN2+ over the 11-year period was 97·4% (95% CI 88·0-99·6). Similar protection was observed against HPV 16/18-associated CIN3-specifically at year 11, vaccine efficacy was 100% (95% CI 78·8-100·0) and cumulative vaccine efficacy was 94·9% (73·7-99·4). During the long-term follow-up, no serious adverse events occurred that were deemed related to the HPV vaccine. The most common grade 3 or worse serious adverse events were pregnancy, puerperium, and perinatal conditions (in 255 [10%] of 2530 women in the unvaccinated control group and 201 [10%] of 2073 women in the HPV vaccine group). Four women in the unvaccinated control group and three in the HPV vaccine group died; no deaths were deemed to be related to the HPV vaccine. INTERPRETATION: The bivalent HPV vaccine has high efficacy against HPV 16/18-associated precancer for more than a decade after initial vaccination, supporting the notion that invasive cervical cancer is preventable. FUNDING: US National Cancer Institute.
引用
- Porras C, Tsang SH, Herrero R, et al. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. Lancet Oncol. 2020. PMID: 33271093. doi:10.1016/S1470-2045(20)30524-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。